Atria Investments Inc Has $1.01 Million Position in Medpace Holdings, Inc. $MEDP

Key Points

• Atria Investments reduced its Medpace stake by 66.2% in the second quarter, selling 3,740 shares and retaining 1,907 shares valued at approximately $1.01 million. Institutional investors and hedge funds collectively own 77.98% of the company.
• Medpace reported quarterly earnings of $4.25 per share, exceeding estimates of $3.98, while revenue rose 17.2% year over year to $707.33 million. The company guided for fiscal 2026 earnings of $17.25–$17.95 per share.
• Insiders sold 55,371 shares worth about $30.88 million during the last quarter, while analysts maintain a consensus “Hold” rating with an average price target of $584.18.

Atria Investments Inc cut its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 66.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,907 shares of the company's stock after selling 3,740 shares during the period. Atria Investments Inc's holdings in Medpace were worth $1,010,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Elyxium Wealth LLC acquired a new position in Medpace in the 4th quarter valued at approximately $30,000. Allied Private Wealth LLC acquired a new position in shares of Medpace during the second quarter worth $31,000. Basecamp Wealth Advisors LLC grew its stake in shares of Medpace by 187.5% in the first quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company's stock worth $33,000 after purchasing an additional 45 shares during the last quarter. Quarry LP bought a new stake in shares of Medpace in the third quarter worth $35,000. Finally, Bayban bought a new stake in shares of Medpace in the fourth quarter worth $44,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Medpace

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of the firm's stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the sale, the general counsel owned 20,343 shares of the company's stock, valued at approximately $9,154,350. This trade represents a 44.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Cornelius P. Mccarthy III sold 1,140 shares of the business's stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $605.37, for a total value of $690,121.80. Following the sale, the director owned 12,275 shares of the company's stock, valued at approximately $7,430,916.75. This represents a 8.50% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 55,371 shares of company stock valued at $30,878,030. 20.50% of the stock is currently owned by corporate insiders.

Medpace Trading Down 2.5%

NASDAQ:MEDP opened at $581.95 on Friday. The stock has a market capitalization of $16.24 billion, a price-to-earnings ratio of 34.11, a PEG ratio of 2.66 and a beta of 1.15. The firm has a fifty day simple moving average of $533.75 and a two-hundred day simple moving average of $491.74. Medpace Holdings, Inc. has a 12 month low of $373.00 and a 12 month high of $677.90.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27. The firm had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business's quarterly revenue was up 17.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. Wall Street Zen lowered Medpace from a "buy" rating to a "hold" rating in a research report on Saturday, April 25th. Barclays set a $600.00 price target on Medpace in a research report on Thursday, July 23rd. TD Cowen increased their price target on Medpace from $419.00 to $492.00 and gave the company a "hold" rating in a research note on Friday, July 24th. Leerink Partners set a $620.00 price objective on Medpace in a research report on Thursday, July 23rd. Finally, BMO Capital Markets lifted their price objective on Medpace from $400.00 to $600.00 and gave the stock a "market perform" rating in a research note on Friday, July 24th. Three analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat, Medpace currently has a consensus rating of "Hold" and an average price target of $584.18.

Medpace Company Profile

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source